Midi Health has raised $50 million in Series C funding led by Advance Venture Partners, bringing total funding to approximately $150 million, Business Insider reported. The round closed in spring 2025.
The virtual menopause and perimenopause care company now serves 20,000 patients weekly, roughly double its patient base from January 2025. CEO Joanna Strober shared that the company has reached a $150 million revenue run rate, up from $60 million at the end of 2024.
Midi offers personalized care including hormonal and non-hormonal medications, blood and genetic testing, lifestyle coaching, and supplements. The company accepts major commercial insurers including UnitedHealthcare, Cigna, and Aetna, but does not work with Medicare or Medicaid plans.
The scaleup is developing an AI-powered search engine for women’s health information. Strober said existing medical search tools sometimes surface outdated or inaccurate women’s health information. The company also launched a preventive care program called AgeWell in May 2025, focused on cardiovascular disease prevention, cancer prevention, and bone and brain health.
Previous investors include Emerson Collective, GV, and angel investors including 23andMe cofounder Anne Wojcicki, Amy Schumer, and Tory Burch. Midi raised its $60 million Series B in April 2024.
The company plans to use the funding for technology development and hiring and training healthcare providers. Strober said Midi has a clear path to profitability but has not determined plans for an initial public offering.
